Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FEJ real-world patient registration study
ChiCTR1900025328Phase 4Recruiting
- Sponsor
- Xiyuan Hospital
- Start
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of colla corii asini in Qi and Blood deficiency (QBD), sponsored by Xiyuan Hospital. Primary endpoints: Related symptoms of syndrome of qi and blood deficiency and Clinical Global Impression. Started Jun 2019; status: recruiting.
02
Drugs
colla corii asini
03
Conditions
Qi and Blood deficiency (QBD)
Beyond the preview
Go deeper on ChiCTR1900025328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025328.